CFTR modulators have shown significant benefits in treating patients with CF (pwCF) who carry eligible CFTR mutations, including the deletion of Phenylalanine at position 508 (ΔF508), which is the most common mutation in pwCF. This evidence concerns the gene CFTR and cystic fibrosis.